The study is said to be the first to demonstrate efficacy for FcRn inhibition in SLE.

PALM BEACH, FL, United States – 4th June 2026 – JFB Construction Holdings reported that XTEND, the company with which it has ...

The results provide validation of the DPP1 inhibition in bronchiectasis and reinforce the drug class’s position in this ...

Au Skarn target footprint grows from ~300 metres to a 2.5-kilometre prospective lithological-magnetic corridor (see Figure 2) ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader ...

Use Attack Drone is part of the next generation of American-built one-way attack drones Powerus recently announced a ...

The company expects to initiate the 12-week Phase II ARCT-032 study in the first half of 2026, enrolling up to 20 participants and focusing on safety and early signs of clinical benefit. For ARCT-810, ...

A total of 35 patients were enrolled and treated, and the median lines of previous treatment were 2 (range, 0-4). The confirmed CNS-ORR was 77.1% (27/35, 95% CI, 59.9 to 89.6), and the CNS-CBR was ...

HYDERABAD: The state government has approved Phase-II of the Comprehensive Road Maintenance Programme (CRMP) in the Core ...